Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-61178104 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose 1: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1. |
| Dose 2: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1. |
| Dose 3: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1. |
| Dose 4: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1. |
| Dose 5: JNJ-61178104 OR Placebo IV | EXPERIMENTAL | Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1. |
| Dose 6: JNJ-61178104 OR Placebo SC | EXPERIMENTAL | Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1. |
| Name | Type | Description |
|---|---|---|
| JNJ-61178104 Intravenous | DRUG | Participants will receive JNJ-61178104 Intravenously on Day 1. |
| JNJ-61178104 Subcutaneous | DRUG | Participants will receive JNJ-61178104 Subcutaneously on Day 1. |
| Placebo | DRUG | Participants will receive placebo on Day 1. |
Inclusion Criteria * Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study * Participant must have a body weight in the range of 50 Kilogram (kg) to 100 kg, inclusiv...
JNJ-61178104 is an investigational small molecule being studied in healthy participants. It is being evaluated for safety and tolerability in a Phase 1 clinical trial. The drug is not approved for any medical condition and is still in clinical development.
JNJ-61178104 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug in healthy participants.
JNJ-61178104 is in Phase 1 clinical development. This phase focuses on evaluating the safety and tolerability of the drug in healthy participants. The drug is investigational and has not been approved by regulatory authorities for any use.
JNJ-61178104 has one completed clinical trial, NCT02758392, which was a Phase 1 study in healthy participants. The trial was conducted in Belgium and enrolled 54 participants. It was a randomized, double-blind, controlled study to evaluate the safety and tolerability of the drug.
JNJ-61178104 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT02758392, was a Phase 1 study in healthy participants to evaluate safety and tolerability, but the drug has not received regulatory approval.